In "Episode 4" of the series on "Present and future of diagnostics in Prostate Cancer", Dr. Rossella Nicoletti (IT) and Prof. Eva Compérat (FR) present the case against renaming Gleason score 6 Prostate Cancer.

They discuss the strong pathological arguments for keeping the "cancer" designation, pointing to the morphological and molecular evidence that supports this classification. Prof. Comperat highlights the risks of causing confusion within the clinical and research communities if Gleason score 6 were no longer considered cancer.

The episode also addresses the potential impact on prostate cancer reporting and the broader implications for treatment decision-making. This discussion presents a compelling counterpoint to the proposal of renaming Gleason score 6, emphasising the importance of consistency in cancer classification.

For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

The panel chair of the EAU guidelines on MIBC, Assoc. Prof. A. Van Der Heijden discusses the new updates with panel members Dr. L. Mertens and Prof. P. Mariappan.

You can view the newest Muscle-invasive and Metastatic Bladder Cancer EAU Guidelines, or download EAU Guidelines App. The app helps to optimise your search with interactive tools to quickly get the answer you need from the best-practice clinical guidelines for urologists. EAU members get full access, and non-members can explore with a 30-day free trial. 

In "Episode 3" of the series on "Present and future of diagnostics in prostate cancer", Assoc. Prof. Paweł Rajwa (PL) and Prof. Scott Eggener (US) engage in a thought-provoking discussion about renaming Gleason 6 (Grade Group 1) prostate cancer.

The episode digs into the reasons why many experts believe this change is necessary, and the potential benefits it could bring to clinical practice, particularly in reducing overdiagnosis/overtreatment and improving patient outcomes. Prof. Eggener discusses the argument that Gleason 6 (Grade Group 1) might not behave like typical cancer, as it rarely leads to metastasis or death, and that renaming it could positively guide management decisions, particularly with active surveillance.

The conversation touches on the implications of this change on prostate cancer screening and how it could alter the way clinicians approach diagnosis and treatment in the future.

For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

At the American Urological Association's 2025 Annual Meeting in Las Vegas, Dr. Félix Guerrero-Ramos (ES) presented the first results from cohort 4 of the SunRISe-1 study, assessing TAR-200 monotherapy in patients with Bacillus Calmette-Guérin (BCG) - unresponsive papillary-only high-risk non-muscle-invasive bladder cancer.

In this episode, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) interviews Dr. Guerrero-Ramos about the study’s design, a detailed discussion of the results, comparisons with other trials such as BOND-003, and the implications for clinical practice. 

For more updates on bladder cancer, please visit our educational platform UROONCO BCa.

For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

At the 2025 American Urological Association (AUA2025) Meeting in Las Vegas, UROONCO RCC associate editor Dr. Riccardo Bertolo (IT) spoke with Prof. Riccardo Autorino (US) about multi-port and single-port surgery options for kidney cancer. 

Prof. Autorino shares expert insights on the key features of both surgical platforms, discussing their advantages and disadvantages, as well as considerations for selecting the most suitable patients for each approach.

For more updates on kidney cancer, please visit our educational platform UROONCO RCC.

For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

At the 2025 American Urological Association (AUA 2025) Meeting in Las Vegas, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talked to Dr. Neal Shore (US) about the CREST study results: Sasanlimab in combination with bacillus calmette-guérin (BCG) improves event-free survival (EFS) versus bacillus calmette-guérin as standard of care in high-risk non- muscle-invasive bladder cancer (NMIBC). 

Dr. Shore explains the study rational, the results of the study, and the take home messages he presented during the meeting.

UROONCO PCa chief editor Dr. Giancarlo Marra talks to Prof. Phil Cornford on the updated EAU Prostate Cancer Guidelines for 2025, specifically on diagnosis and localised disease.

Their conversation focuses on key updates in active surveillance, diagnosis, and treatment of localised disease.

In "Episode 2" of the series on "Present and future of diagnostics in prostate cancer," Prof. Monique Roobol (NL) and Dr. Tamás Fazekas (HU) review the ongoing debate surrounding prostate cancer screening.

They review the history and development of screening strategies, including the key findings from early trials and the progression toward more personalised, risk-stratified approaches.

Prof. Roobol discusses the significance of PSA testing and how it serves as a tool for initial risk stratification, while also addressing the role of advanced techniques like MRI and novel biomarkers in improving screening accuracy. The episode also highlights the need to balance the benefits of early detection with the risks of overdiagnosis, and the speakers share their insights into how the latest clinical trials are shaping the future of prostate cancer screening.

For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

In "Episode 1" of the series "Present and future of diagnostics in prostate cancer," Assoc. Prof. Juan Gomez Rivas (ES) and Dr. Elena Castro (ES) explore the importance of genomics and biomarkers in localised prostate cancer.

The episode reviews why these diagnostic tools are pivotal in the changing landscape of prostate cancer, offering a deeper understanding of their current and future role in patient care.

Assoc. Prof. Gomez Rivas and Dr. Castro discuss how these advancements in molecular profiling and biomarker testing can revolutionise the diagnosis and management of prostate cancer. Their conversation highlights the evolving nature of prostate cancer diagnosis, offering valuable perspectives on how genomics and biomarkers are shaping the future of personalised treatment strategies.

For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

In this episode of EAU Podcasts, Prof. Guy Bogaert and Prof. Christian Radmayr, the vice-chair and chair of the Paediatric Urology Guidelines Panel, discuss the latest updates to the EAU Guidelines on paediatric urology. Tune in to learn about the 2025 updates.